First identify what ended

The STEP 1 extension followed 327 participants after the original 68-week trial. Both study treatment and the structured lifestyle intervention ended, followed by 52 weeks of observation. This was an exploratory extension in a subset of trial completers, not a newly randomized comparison of different stopping strategies.

The former semaglutide group regained about two-thirds of its earlier weight loss on average; mean weight remained 5.6% below baseline. Several cardiometabolic measures moved back toward baseline. Because treatment and structured support stopped together, these observations should not be presented as isolating the effect of withdrawing medication alone.

An average is a description, not a forecast

When reading follow-up research, S7 suggests asking who stayed in the analysis, what support continued, and whether the next comparison was randomized. These details are part of the result, not fine print. A single average does not tell an individual what will happen, and the word extension does not mean that all original participants were followed in the same way.

It also helps to keep two questions separate: what happened after this particular trial ended, and what strategy would produce a better long-term outcome? A follow-up can inform the first question while leaving the second unresolved. The evidence is more useful when that distinction stays visible.

Duration does not become a cycle

Do not turn study observation periods into a personal start-stop schedule. This article is educational commentary, not advice to begin, discontinue or cycle a medicine. Treatment decisions belong with a qualified clinician. The illustration represents the passage of time, not a clinical trajectory or tested schedule.